Bringing Karnataka’s Artificial Intelligence Vision to Life
Elets Technomedia, in partnership with eGov magazine and the Department of Information Technology, Biotechnology, and Science & Technology of the Government of Karnataka, is set to release a unique souvenir magazine focused on Artificial Intelligence (AI) at the...
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk's blockbuster weight-loss drug, semaglutide, which is sold...
Alkem Laboratories injects $70 million into the US market, leveraging its Enzene capabilities.
Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India's top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move...
Glenmark Pharmaceuticals Inc., USA is set to introduce Eribulin Mesylate Injection in 1mg/2mL single-dose vials, with a concentration of 0.5 mg/mL.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5...
Zydus Lifesciences introduces the country’s inaugural trivalent vaccine to combat Influenza in India.
The global market for seasonal influenza vaccines is expected to experience significant growth, with a projected value of $24.1 billion by 2035, up from $10.2 billion in 2025, at a compound annual growth rate (CAGR) of 9%. Major multinational vaccine manufacturers,...
Glenmark introduces the United States’ first complex generic cancer medication.
Glenmark Pharmaceuticals has made a significant breakthrough in the US market by launching the first complex generic cancer drug, Fulvestrant Injection, 250 mg/5 mL (50 mg/mL). This is a generic version of Faslodex, an injectable medication used to treat hormone...
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India's pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing...
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older....
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India's pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing...
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce...
CDSCO Panel Approves Sun Pharma’s Phase IV Clinical Trial for Dual Release Pantoprazole in Treating Gastroesophageal Reflux Disease (GERD)
Sun Pharma, a leading pharmaceutical company, has announced that its Phase IV study on dual release pantoprazole for the treatment of Gastroesophageal Reflux Disease (GERD) has received acceptance from the Central Drugs Standard Control Organization (CDSCO) panel....
Volini by Sun Pharma Introduces ‘Uparna’, a Groundbreaking Initiative for Devotees Traveling to Pandharpur
Sun Pharmaceutical Industries Limited, India's leading pharmaceutical company, has launched a unique initiative through its pain relief brand, Volini. During the annual Pandharpur Wari pilgrimage in Maharashtra, one of the oldest and most significant spiritual...
Delhi High Court Grants Sun Pharma Reprieve by Restraining Use of BERIVITAL, BEZOLIC, and DOZE-30 Due to Trademark Infringement
The Delhi High Court has granted relief to Sun Pharma, a prominent pharmaceutical company, by barring the use of three trademarks - BERIVITAL, BEZOLIC, and DOZE-30 - due to trademark infringement. This decision is a significant victory for Sun Pharma, as it protects...
Sun Pharma Reports Favorable Phase 3 Trial Outcomes for Tildrakizumab in Treating Psoriatic Arthritis
Sun Pharma has announced positive top-line results from two phase 3 clinical trials, INSPIRE-1 and INSPIRE-2, evaluating the efficacy and safety of tildrakizumab 100 mg (Ilumya) in patients with active psoriatic arthritis. The studies, which enrolled over 800...
Authorities with the DCA have seized counterfeit Levipil 500 tablets.
The Telangana State Drugs Control Administration (DCA) has cracked down on counterfeit medication in the region, seizing fake Levipil 500 tablets, which are used to treat epilepsy. The tablets were falsely labeled as products of Sun Pharma Laboratories Ltd, a...
Fake versions of Sun Pharma’s cholesterol-lowering medications confiscated in Hyderabad
In a significant crackdown on counterfeit pharmaceuticals, the Telangana Drugs Control Administration (DCA) has seized fake versions of heart medications Rosuvas F 20 and Rosuvas F 10 in Hyderabad's Koti area. The counterfeit cholesterol-lowering drugs, labeled under...
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk's blockbuster weight-loss drug, semaglutide, which is sold...
Natco Pharma files lawsuit against Novo Nordisk in Delhi courts regarding intellectual property dispute over Semaglutide.
Natco Pharma, an Indian pharmaceutical company, has filed a lawsuit against Novo Nordisk, a Danish multinational pharmaceutical company, in a Delhi court over intellectual property rights related to semaglutide. Semaglutide is a medication used to treat type 2...
Natco Pharma names TC Mallikarjun as its new Vice President.
Natco Pharma, a leading pharmaceutical company, has announced the appointment of TC Mallikarjun as Vice President - Quality Control (QC) at its Kothur Pharma Division. This appointment is a significant development for the company, as it continues to strengthen its...
Access to the Request Has Been Denied
It appears that you have encountered an error while trying to access the website www.tipranks.com. The error message indicates that your request was blocked by Link11 Web Application Security, which is a security system designed to protect websites from malicious...
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company's plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
Divis Laboratories signs long-term manufacturing and supply pact with international pharmaceutical company.
Divis Laboratories has secured a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the terms of the agreement, Divis will manufacture and supply advanced intermediates to the pharma company, with the details of the commercial...
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic...
Bringing Karnataka’s Artificial Intelligence Vision to Life
Elets Technomedia, in partnership with eGov magazine and the Department of Information Technology, Biotechnology, and Science & Technology of the Government of Karnataka, is set to release a unique souvenir magazine focused on Artificial Intelligence (AI) at the...
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk's blockbuster weight-loss drug, semaglutide, which is sold...
Alkem Laboratories injects $70 million into the US market, leveraging its Enzene capabilities.
Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India's top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move...
Glenmark Pharmaceuticals Inc., USA is set to introduce Eribulin Mesylate Injection in 1mg/2mL single-dose vials, with a concentration of 0.5 mg/mL.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5...
Zydus Lifesciences introduces the country’s inaugural trivalent vaccine to combat Influenza in India.
The global market for seasonal influenza vaccines is expected to experience significant growth, with a projected value of $24.1 billion by 2035, up from $10.2 billion in 2025, at a compound annual growth rate (CAGR) of 9%. Major multinational vaccine manufacturers,...
Glenmark introduces the United States’ first complex generic cancer medication.
Glenmark Pharmaceuticals has made a significant breakthrough in the US market by launching the first complex generic cancer drug, Fulvestrant Injection, 250 mg/5 mL (50 mg/mL). This is a generic version of Faslodex, an injectable medication used to treat hormone...
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India's pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing...
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older....
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce...
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and...
Cipla’s CEO responds to tariff threats, highlighting the company’s diversified business model as a key strength.
Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla's CEO, Umang Vohra, emphasized that the company has "one of the most well-diversified models" in the...
Global Digoxin Industry Analysis: An In-Depth Report Featuring Key Players Such as Pfizer, Novartis, and Mylan
The Global Digoxin Market study, recently introduced by HTF MI, provides a comprehensive overview of the product and industry scope, as well as an in-depth analysis of the market outlook and status from 2025 to 2031. The market is segmented by key regions, including...
Lupin Splits Off Its Consumer Healthcare Business to Form Independent Company
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Amit Patel has been promoted to lead Consumer Marketing Excellence as its new Head.
Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric...
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth...
Apollo Hospitals Hyderabad celebrates 37 years of excellence, with Sangita Reddy and Tejesvi Rao Veerepalli looking back on a legacy built on innovative healthcare and unwavering trust.
Apollo Hospitals in Hyderabad recently celebrated its 37th anniversary, marking a significant milestone in its journey as a pioneering healthcare institution in India. The hospital was among the first private healthcare institutions in the country to provide...
Garmin and Apollo HealthAxis strengthen their strategic partnership.
Garmin and Apollo HealthAxis have announced a deepening of their strategic collaboration. The partnership aims to reimagine Indian healthcare by integrating Garmin's wearable technology with Apollo HealthAxis's healthcare services. The collaboration will focus on...
India is on the cusp of becoming the globe’s premier healthcare hub.
Dr. Prathap C Reddy, Founder-Chairman of Apollo Hospitals and Chancellor of Apollo University, has expressed his confidence that India is on the verge of becoming the world's healthcare capital. He made this statement while addressing students and faculty at Apollo...
Apollo Hospital reaches milestone of 600 successful pediatric liver transplants, commemorated with book release, as reported by The Week.
Two doctors from Apollo Hospital in New Delhi, Dr. Smita Malhotra and Dr. Anupam Sibal, have authored a book titled "Transplanting Hope" to commemorate the hospital's 600th pediatric liver transplant. The book is an anthology of 25 stories that showcase the grit,...
Apollo remains poised for consistent growth in earnings.
According to a report by Reliance Securities, Apollo Hospitals is poised for significant growth and expansion in the future. The hospital chain is expected to benefit from several key factors, including the expansion of its bed capacity, an increase in international...
Apollo Hospitals in India plans to double its investments in artificial intelligence after surpassing profit expectations.
Apollo Hospitals, one of India's largest private healthcare providers, has announced plans to double its investments in artificial intelligence (AI) over the next two years. The move is aimed at improving patient outcomes, enhancing operational efficiency, and...
Future Female Forward | Apollo HealthCo’s Shobana Kamineni: ‘We’re aiming for a phenomenal, blockbuster demerger’
Shobana Kamineni, Executive Chairperson of Apollo HealthCo, has made a bold prediction that the company's turnover will soon surpass that of Apollo Hospitals. This statement was made at the CNBC-TV18's Future Female Forward event in Bengaluru, where Kamineni...
Nourishment comes first for optimal well-being
The importance of food in maintaining overall health and wellbeing has been emphasized for centuries. As stated in the ancient Sanskrit text, Charaka Samhita, "Annam hi jeevanam" or "food is life itself". This phrase was recently quoted by Dr. Anupam Sibal, Group...
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older....
Biggest Global Pharma Firms of 2025: Ranking the Top 5
The pharmaceutical industry is a vital sector that produces life-saving medicines, vaccines, and treatments that improve global health. The top five largest pharmaceutical companies in the world, as of 2025, are Pfizer, Johnson & Johnson, AbbVie, Merck & Co., and...
Does Enanta’s Lawsuit and PADCEV Trial’s Positive Outcomes Alter Pfizer’s (PFE) Investment Storyline?
Pfizer, a leading pharmaceutical company, is facing a crucial period as it navigates through patent litigation and promising cancer trial results. Enanta Pharmaceuticals has initiated a lawsuit against Pfizer in the European Unified Patent Court, alleging infringement...
PFE transformation as a market catalyst fuels Institutional Tactics with a Liquidity Pulse, revolutionizing asset management strategies.
The key findings for Pfizer Inc. (NYSE: PFE) indicate a strong sentiment in the near and mid-term, but a weak long-term outlook. The analysis reveals no clear price positioning signal, but the upside opportunity looks excellent as long as the converted support holds....
Work Halts at David Werner’s Conversion of Metro Loft’s Pfizer Headquarters
A suspected fire at the former Pfizer headquarters in Manhattan, currently under construction for a residential conversion, prompted a response from authorities. The incident occurred at 235 East 42nd Street, where Nathan Berman's Metro Loft and David Werner are...
Makers of generic drugs agree to pay 71 million dollars to settle allegations of price-fixing.
Glenmark Pharmaceuticals Inc. USA and Pfizer Inc., along with its generic-drug unit Greenstone LLC, have reached a settlement agreement to resolve price-fixing claims brought by direct purchasers of generic drugs. According to the terms of the agreement, Glenmark...
ZDS-Varenicline, a smoking cessation medication developed by Zydus Lifesciences, receives approval from Health Canada, as reported by geneonline.com.
Zydus Lifesciences, a leading pharmaceutical company, has received approval from Health Canada for its smoking cessation drug, ZDS-Varenicline. This approval marks a significant milestone for the company, as it expands its presence in the Canadian market....
Burn Pain Treatment Industry: Research, Therapies, and Key Players Including Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, and Trio Li.
The burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. According to DelveInsight, the market is driven by the rising demand for effective pain management therapies for burn patients. Burn pain...
Fortis Hospital in Mohali hosts the zonal finals of ‘PSYCH-ED 2025’
Fortis Hospital, Mohali, recently hosted the zonal finals of the 8th edition of its national psychology quiz program, "PSYCH-ED, 2025". The event saw participation from over 900 schools across India, with more than 12,000 students from 190+ cities taking part in the...
Fortis acquires Shrimann hospital in a massive Rs 462 crore deal
Fortis Healthcare has expanded its presence in Punjab by acquiring the 228-bed Shrimann Superspecialty Hospital for a consideration of Rs 462 crore. This marks the fifth hospital of Fortis in Punjab, with existing hospitals in Ludhiana, Mohali, and Amritsar. The...
Fortis Hospital ordered to compensate Rs 50 lakh for medical negligence
The District Consumer Disputes Redressal Commission in Chandigarh has held Fortis Hospital in Mohali and one of its doctors guilty of medical negligence. The commission has ordered the hospital to pay a compensation of Rs 50 lakh along with 9% interest per annum to...
Fortis and Agilus Enhance Genomic Testing Capabilities with Additional Genexus System, Accelerating Cancer Diagnosis.
Fortis and Agilus have partnered to enhance genomic testing capabilities with the installation of a second Genexus system. This move is expected to significantly improve the speed and accuracy of cancer diagnosis. The Genexus system is a next-generation sequencing...
Fortis Hospital, Manesar Achieves Breakthrough in Treating 38-Year-Old Stage 4 Head and Neck Cancer Patient with Innovative Targeted Oral Therapy
A 38-year-old man diagnosed with stage 4 head and neck cancer has successfully undergone treatment at Fortis Hospital, Manesar, using targeted oral therapy. The patient, who was initially diagnosed with a tumor in his throat, had been experiencing symptoms such as...
On World Kidney Cancer Day, physicians at Mohali’s Fortis Hospital launch an initiative to educate the public about the causes and symptoms of kidney cancer.
On June 19, World Kidney Cancer Day, doctors at Fortis Hospital in Mohali are raising awareness about the increasing incidence of kidney cancer in India. They are highlighting the symptoms of the disease, which include abdominal pain, swelling in the abdomen,...
Manipal and Fortis are engaging in discussions to secure Rs 5,000 crore for a potential acquisition of Sahyadri Hospitals.
The bidding process for Sahyadri Hospitals, a multispecialty hospital chain, is nearing its deadline of June 22. Interested bidders, including Manipal Health Enterprises and Fortis Healthcare, are in talks with foreign lenders to secure financing of up to Rs 5,000...
Fortis Healthcare launches state-of-the-art outpatient clinic for specialized care in Guwahati, as reported by Healthcare Asia Magazine
Fortis Healthcare, a leading integrated healthcare delivery service provider, has launched a super-speciality outpatient clinic in Guwahati, Assam. The clinic, which is the first of its kind in the region, aims to provide access to quality healthcare services to the...